BCI Payer EducationVideo Categories: PMO Interview with the Innovator Series: Volume 8
Dr. Sanjiv Agarwala brings up the potential issue of toxicity that may arise in combining immunotherapies and argues that the benefits outweigh the risks.
How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer [ Read More ]